{"id":39551,"date":"2020-09-04T00:00:00","date_gmt":"2020-09-04T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2020\/09\/04\/child-cancer-survivors-hearing-loss-linked-to-cognitive-deficits\/"},"modified":"2020-09-08T16:10:09","modified_gmt":"2020-09-08T16:10:09","slug":"child-cancer-survivors-hearing-loss-linked-to-cognitive-deficits","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2020\/09\/04\/child-cancer-survivors-hearing-loss-linked-to-cognitive-deficits\/","title":{"rendered":"Child Cancer Survivors&#8217; Hearing Loss Linked to Cognitive Deficits"},"content":{"rendered":"<h3>Findings seen in survivors of childhood cancer independent of the neurotoxic treatment received<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>FRIDAY, Sept. 4, 2020 (HealthDay News) &#8212; Severe hearing impairment (HI) in childhood cancer survivors is associated with neurocognitive deficits, according to a study recently published in <i>JAMA Oncology<\/i>.<\/p>\n<p>Johnnie K. Bass, Ph.D., from St. Jude Children&#8217;s Research Hospital in Memphis, Tennessee, and colleagues assessed hearing and neurocognitive function in 1,520 long-term survivors of childhood cancer (five or more years) participating in the St. Jude Lifetime Cohort Study (April 25, 2007, to June 30, 2017).<\/p>\n<p>The researchers found that the prevalence and risk for severe HI among survivors were higher in those exposed to platinum-only (relative risk [RR], 1.68; 95 percent confidence interval [CI], 1.20 to 2.37) or cochlear radiotherapy (RR, 2.69; 95 percent CI, 2.02 to 3.57) versus the no-exposure group. There was an association between severe HI and deficits in verbal reasoning skills (no-exposure group: RR, 1.11; 95 percent CI, 0.50 to 2.43; platinum-only exposure group: RR, 1.93; 95 percent CI, 1.21 to 3.08; cochlear radiotherapy exposure group: RR, 2.00; 95 percent CI, 1.46 to 2.75), verbal fluency (no-exposure group: RR, 1.86; 95 percent CI, 1.19 to 2.91; platinum-only exposure group: RR, 1.83; 95 percent CI, 1.24 to 2.71; cochlear radiotherapy exposure group: RR, 1.45; 95 percent CI, 1.09 to 1.94), visuomotor speed (no-exposure group: RR, 1.87; 95 percent CI, 1.07 to 3.25; platinum-only exposure group: RR, 3.10; 95 percent CI, 1.92 to 4.99; cochlear radiotherapy exposure group: RR, 1.40; 95 percent CI, 1.11 to 1.78), and mathematics skills (no-exposure group: RR, 1.90; 95 percent CI, 1.18 to 3.04; platinum-only exposure group: RR, 1.63; 95 percent CI, 1.05 to 2.53; cochlear radiotherapy exposure group: RR, 1.58; 95 percent CI, 1.15 to 2.18) versus survivors with normal hearing or with mild HI.<\/p>\n<p>&#8220;Early screening and intervention for HI may facilitate the development<br \/>\nand maintenance of neurocognitive function and identify individuals at risk for impairment,&#8221; the authors write.<\/p>\n<p>One author disclosed financial ties to the pharmaceutical industry.<\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/article-abstract\/2768632\" target=\"_new\" rel=\"noopener noreferrer\">Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/article-abstract\/2768629\" target=\"_new\" rel=\"noopener noreferrer\">Editorial (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2020 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Findings seen in survivors of childhood cancer independent of the neurotoxic treatment received<\/p>\n","protected":false},"author":6,"featured_media":39635,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-39551","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/39551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=39551"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/39551\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/39635"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=39551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=39551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=39551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}